Axcella Addresses Metabolic Disease Quickly With GRAS Candidates
Non-IND Development Pathway May Save Time And Money
Emerging Company Profile: Axcella uses Generally Recognized As Safe (GRAS) amino acids to create drug candidates for hepatic encephalopathy, NASH and other diseases.
You may also be interested in...
Public Company Edition: Trevi Therapeutics was the first out of the gate on 7 May, but four more biopharma firms went public in the US on 8 May, while just 13 IPOs launched between January and April. Also, new financings include debt for BMS, Bausch and Intercept.
As industry closes in on the first approved drug therapy for non-alcoholic steatohepatitis, our infographic details the dozens of companies testing numerous mechanisms for the multi-factorial disease.
Biotech gets $190m up front in partnership that will discover small molecule RNA-targeted therapies against a range of targets selected by Roche. Arrakis thinks its technology can drug difficult-to-reach targets.